Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Volpara (ASX:VHT) share price in focus on latest Australian contract win

The Volpara Health Technologies Ltd (ASX:VHT) share price is in focus after the ASX healthcare share announced a new contract.

The Volpara Health Technologies Ltd (ASX: VHT) share price is in focus after the ASX healthcare share announced a new contract.

Volpara provides software relating to breast screening, analysis and practice management.

Breastscreen Victoria win

Volpara announced that it had won a five-year contract for A$1.4 million (NZ$1.53 million) in total contract value (TCV) with BreastScreen Victoria.

This contract includes Volpara Analytics, which the ASX share described as artificial intelligence (AI) quality software that “assesses every mammogram image for appropriate positioning, compression and radiation dose.”

Volpara believes this will lead to a higher-quality screening programme and improved personalised care for women.

This contract expands Volpara’s presence in Australia – it already has contracts with BreastScreen Queensland, BreastScreen South Australia , I-MED and Sonic Healthcare Ltd (ASX: SHL).

BreastScreen Victoria operates in more than 50 locations across the state and diagnoses 37% of all breast cancers in Victoria. This win is a positive for the Volpara share price, in my opinion.

Installation of Volpara’s software at BreastScreen Victoria is expected to be completed within three to six months. It includes annual payments and is anticipated to contribute to revenue growth in FY24. The ASX share noted that the customer has the right to terminate the contract during the initial three-month period if “certain product metrics are not met”. Hopefully that doesn’t happen.

Management comments

The Volpara CEO and Managing Director Teri Thomas said:

We are thrilled to have BreastScreen Victoria join the ranks of Australian screening programmes and other healthcare providers already using Volpara’s AI-powered software.

Australia boasts one of the world’s highest breast cancer survival rates after five years at 91%. Both private and public screening programmes, like BreastScreen Victoria, deserves praise for their commitment to improving quality and detecting cancer earlier through technology investments.

Final thoughts on the Volpara share price

While the ASX healthcare share has risen less than 1% in response to this, it’s another positive on a list of positives.

It has done very well in the US, so it’s good to see that the company is winning more contracts outside of that market.

The more market share it can capture, the better chance it has of increasing its average revenue per user (ARPU). I believe it’s one of the most promising ASX growth shares around.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content